Methadone moves to your local pharmacy—if your state allows it
H.R. 9790 — Modernizing Opioid Treatment Access Act 2.0 of 2026 · Filed by Donald Norcross (D-NJ) · 2 cosponsors · Introduced Jul 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands access to methadone for opioid addiction treatment by allowing qualified addiction medicine doctors and psychiatrists to prescribe methadone through retail pharmacies (not just specialized opioid treatment clinics), with electronic prescribing and state opt-out authority. Patients can receive methadone via pharmacy while continuing other addiction treatment, and the DEA must report annually on registrations, revocations, and pharmacy ordering patterns.
Why we flagged it
The bill's core mechanism is regulatory deregulation of methadone prescribing to increase treatment access for opioid use disorder—a public health objective. It is not a tax provision, appropriation, or narrow carve-out; it is a substantive policy change to expand a medical treatment pathway.
What the text implies
- Pharmacy-based methadone dispensing may reduce stigma and increase treatment initiation, but could also increase diversion risk if prescriber oversight or pharmacy compliance is weak; DEA reporting may not capture real-world diversion patterns quickly enough.
- State opt-out authority creates a patchwork of access—some states may block the program entirely, leaving residents in those states without the expanded option despite federal authorization.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (methadone suppliers); retail pharmacy chains and independent pharmacies; addiction medicine practitioners and psychiatrists